Trial Profile
CRF Receptor Antagonist for PTSD and Related Sleep Disturbances in Women
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Verucerfont (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Acronyms AFTER
- 26 Mar 2013 New trial record
- 01 Mar 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.